- SalvaRx Group Plc is a Isle of Man-based company. The Company engaged in drug discovery and development, focused on immune oncology. The Company invests in novel cancer immuno-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		-47.06%	-

19-09-26	SalvaRx Evaluates Takeover Opportunities	CI
19-09-26	Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	CI

Market Cap	1.65M 1.43M 1.32M 1.23M 2.3M 157M 2.35M 15.61M 6.06M 76.16M 6.2M 6.07M 265M	P/E ratio 2017	-4.13x	P/E ratio 2018	83x
Enterprise value	2.41M 2.09M 1.92M 1.8M 3.37M 230M 3.43M 22.83M 8.86M 111M 9.07M 8.87M 387M	EV / Sales 2017	-	EV / Sales 2018	-
Free-Float	20.33%	Yield 2017 *	-	Yield 2018	-

19-09-26	SalvaRx Evaluates Takeover Opportunities	CI
19-09-26	Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	CI
19-06-28	Salvarx Group plc Reports Earnings Results for the Full Year Ended December 31, 2018	CI
19-01-07	Portage Biotech Inc. (OTCPK:PTGE.F) completed the acquisition of SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile.	CI
18-09-27	SalvaRx Group plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	CI
18-08-13	Portage Biotech Inc. (OTCPK:PTGE.F) (‘Portage’) entered into a conditional sale agreement to acquire SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile for $80.5 million.	CI
18-06-28	SalvaRx Group plc Announces Consolidated Earnings Results for the Year Ended December 31, 2017	CI
18-06-28	SalvaRx Seeks Acquisitions	CI
18-06-26	SalvaRx Announces an Unsecured $1 Million Loan	CI
17-09-27	SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017	CI
17-06-30	SalvaRx Group plc Announces Final Audited Consolidated Earnings Results for the Year Ended December 31, 2016	CI
17-06-30	SalvaRx Seeks Investments	CI
17-05-30	SalvaRx Group plc Treats First Patient INT230-6 as Part of A Phase 1/2 International Clinical Study	CI

20-10-14	SalvaRx : Portage Issues Common Shares and Warrants in Settlement of SalvaRx Loan Note Obligations	AQ
19-09-27	SalvaRx : Half Yearly Report 30 June 2019 RNS	PU
19-09-26	SalvaRx : RNS SalvaRx Group PLC interim report 30 June 2019	PU

SalvaRx Group plc Stock

Stocks

SALV

IM00BZ4SS228

Biotechnology & Medical Research

Valuation: SalvaRx Group plc

Latest news : SalvaRx Group plc

Press Releases: SalvaRx Group plc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALVARX GROUP PLC	-.--%	-47.06%	-	-	2.16M
ARGENX SE	-0.68%	+9.22%	+47.64%	+107.96%	54.5B
WUXI APPTEC CO., LTD.	-2.63%	-6.29%	+44.26%	+38.61%	41.73B
BIONTECH SE	+1.17%	-2.96%	-20.62%	-20.82%	21.87B
INSMED INCORPORATED	+5.17%	-4.52%	+40.12%	+400.20%	21.47B
WUXI BIOLOGICS (CAYMAN) INC.	-2.20%	-10.47%	+10.21%	-33.65%	15.79B
GENMAB A/S	-0.03%	+4.27%	+11.41%	-39.82%	15.29B
EXELIXIS, INC.	+2.42%	+9.17%	+23.46%	+175.99%	13.32B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.77%	+1.00%	+15.23%	-	11.53B
SUMMIT THERAPEUTICS INC.	+1.28%	-3.84%	-33.72%	+716.57%	11.09B
Average	+0.84%	-6.00%	+15.33%	+168.13%	20.66B
Weighted average by Cap.	+0.22%	-0.10%	+25.67%	+127.05%

	2017	2018
Net sales	-	-
Net income	-1.74M -1.51M -1.39M -1.3M -2.43M -166M -2.48M -16.49M -6.4M -80.43M -6.55M -6.41M -280M	342K 296K 273K 255K 477K 32.61M 486K 3.23M 1.25M 15.77M 1.28M 1.26M 54.81M
Net Debt	2.22M 1.92M 1.77M 1.66M 3.1M 212M 3.16M 21.01M 8.15M 102M 8.34M 8.16M 356M	763K 660K 608K 570K 1.06M 72.76M 1.08M 7.21M 2.8M 35.19M 2.86M 2.8M 122M